CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:NK cell adaptation in the tumor microenvironment: Insights for NK cell-based immunotherapy.
NK cell adaptation in the tumor microenvironment: Insights for NK cell-based immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自然杀伤(NK)细胞是免疫系统中的关键第一响应者,通过直接清除恶性细胞和调节更广泛的免疫功能来协调抗肿瘤反应。其能够在无需MHC限制性新抗原呈递的情况下识别应激靶标,加之良好的安全性特征,奠定了对NK细胞疗法日益增长的热情。
然而,NK细胞疗法在实体瘤中的临床疗效受到肿瘤微环境(TME)驱动的免疫抑制、代谢竞争和细胞内在耗竭机制的阻碍。在本综述中,我们概述了从NK细胞的发现到其作为癌症免疫治疗突破性靶点的历程。随后,我们提供了NK细胞生物学的综合框架,从稳态调节到TME驱动的表观遗传、转录和代谢适应。
值得注意的是,我们讨论了近期关于NK细胞亚群异质性及其与肿瘤细胞、免疫细胞和肠道微生物组相互作用的研究。最后,我们批判性地评估了临床进展,同时强调了合理设计的、基于机制的联合治疗策略以应对肿瘤逃逸通路的必要性。本综述以工程化解决方案的前瞻性视角作结,旨在释放NK细胞在实体瘤和血液系统恶性肿瘤中的全部治疗潜力。
Natural killer (NK) cells serve as critical first responders within the immune system, orchestrating antitumor responses by directly eliminating malignant cells and modulating broader immune functions. Their capacity to recognize stressed targets without MHC-restricted neoantigen presentation, together with a favorable safety profile, underpins growing enthusiasm for NK cell based therapeutics.
Nonetheless, the clinical efficacy of NK-cell-based therapies in solid tumor has been hindered by tumor microenvironment (TME)-driven immunosuppression, metabolic competition, and cell-intrinsic exhaustion mechanisms. In this review, we outline the journey from the discovery of NK cells to their role as a breakthrough target in cancer immunotherapy.
We then provide a comprehensive framework of NK cell biology, from homeostatic regulation to TME-driven epigenetic, transcriptional, and metabolic adaptations.
Notably, we discuss recent investigations into NK cell subset heterogeneity and their interactions with tumor cells, immune cells and the gut microbiome.
Finally, we critically evaluated clinical progress while highlighting the imperative for rationally designed, mechanism-based combinations that address tumor escape pathways. The review concludes with a forward-looking perspective on engineering solutions to unlock the full therapeutic potential of NK cells across solid tumors and hematologic malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。